Radiation and chemotherapy for high ‐risk lower grade gliomas: Choosing between temozolomide and PCV

ConclusionsAt present, we conclude that current evidence does not support the widespread use of TMZ over PCV for all patients with high ‐risk LGG, and we instead recommend tailoring chemotherapy recommendation based onIDH status, favoring adjuvant PCV for patients with anyIDH mutant tumors, both those that harbor 1p/19q codeletion and those non ‐1p/19q codeleted. Given the critical role radiation plays in the treatment of LGG, radiation oncologists should be actively involved in discussions regarding chemotherapy choice in order to optimize treatment for their patients.

Source: Cancer Medicine - November 6, 2019 Category: Cancer & Oncology Authors: Susan G. R. McDuff, Jorg Dietrich, Katelyn M. Atkins, Kevin S. Oh, Jay S. Loeffler, Helen A. Shih Tags: REVIEW Source Type: research